Amber Therapeutics announces successful first-in-human implants of Amber-UI: an intelligent, closed-loop bioelectrical therapy for urge and mixed urinary incontinence
January 24, 2023Business Services
London, UK and Antwerp, Belgium. 24th January 2023 – Amber Therapeutics (‘Amber’ or the ‘Company’), a University of Oxford spinout …
2022 Novo Holdings Seed Investments team Review/Business Update
January 24, 2023Business Services
Copenhagen, Denmark, 24 January 2023 – Seed Investments, the early stage investment and company creation team of Novo Holdings, today …
Global Company Foot Science International Choose Onyx Health
January 24, 2023Business Services
Leading orthotics company Foot Science International has joined forces with creative agency Onyx Health to launch a new medical education …
Neuraxpharm completes its presence in Benelux by opening an affiliate in Brussels to cover Belgium and Luxembourg
January 24, 2023Business Services
Brussels and Düsseldorf – January 24, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the …
Europe plans further antibiotic shortage countermeasures
January 24, 2023Medical Communications
With respiratory infections increasing, an ongoing cost of living crisis and the Russia-Ukraine conflict, officials throughout Europe are beginning to …
WHO issues a “call to action” after cough syrup deaths
January 24, 2023Medical Communications
WHO has released an urgent “call to action” to all 194 WHO member states in order to try and prevent, …
TheracosBio’s oral drug approved by FDA for adults with type 2 diabetes
January 24, 2023Research and Development
TheracosBio has announced that the first oral SGLT2 inhibitor, bexaflilozin, has been approved by the FDA for the treatment of …
Novo Nordisk accused of violating FDA’s Fair Balance advertising policy
January 24, 2023Sales and Marketing
Advocacy group, the Physicians Committee for Responsible Medicine, has accused Novo Nordisk of breaching FDA’s Fair Balance policy after Novo …
Modus Therapeutics submits patent application for sevuparin in kidney disease
January 23, 2023Business Services
STOCKHOLM, SWEDEN – 23 January 2023: Modus Therapeutics AB (“Modus”), a company developing innovative treatments for patients with major unmet …
Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)
January 23, 2023Business Services
Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound …
First Indian intranasal COVID-19 vaccine about to launch
January 23, 2023Medical Communications
Indian biotech company Bharat Biotech plans to launch its new intranasal COVID-19 vaccine iNCOVACC on the 26 January 2023 ‒ …
FDA awards CardioRenal Systems Breakthrough Device Designation for RenalGuard Therapy
January 23, 2023Medical Communications
The FDA has granted Breakthrough Device Designation for US-based medical technology company CardioRenal for their RenalGuard Therapy device, used to …
FDA grants Accelerated Approval for Seagen’s colorectal cancer treatment
January 23, 2023Research and Development
Seagen Inc has been given FDA Accelerated Approval for its colorectal drug TUKYSA (tucatinib) after reviewing positive data from the …
AI and motion capture technology used to monitor movement disorders
January 23, 2023Research and Development
A team of researchers have been developing a monitoring system to assess the progression of movement disorders. The new technology …
FDA rejects accelerated approval for Eli Lilly’s Alzheimer’s drug, donanemab
January 20, 2023Research and Development
Eli Lilly has announced that its accelerated approval bid for Alzheimer’s disease drug, donanemab, has been rejected by the FDA. …
Merck attempts to reduce levels of carcinogenic compounds in diabetes drugs
January 20, 2023Medical Communications
Pharmaceutical company Merck has announced that it is attempting to reduce levels of a cancer-causing compound which has been found …
Intas Pharmaceuticals under FDA scrutiny after oversight in GMP documents
January 20, 2023Manufacturing and Production
India-based manufacturer Intas Pharmaceuticals has been issued a Form 483 by the FDA after three investigators found a “cascade of …
Alnylam and PTC Therapeutics’ rare disease drugs given backing by NICE
January 20, 2023Medical Communications
Alnylam’s Amvuttra and PTC Therapeutics’ Translarna will be available to patients through the NHS after being backed by NICE, despite …
Genentech announce positive results from phase 3 IMbrave050 study
January 19, 2023Research and Development
Genentech, based in California, US, has announced positive results from its phase 3 IMbrave050 trial, after the study met its …
Abbott secures FDA approval for Navitor TAVI device
January 19, 2023Medical Communications
US-based medical device firm Abbott has secured FDA approval for Navitor to treat people with aortic stenosis who are at …
